Skip to content

Evaluation of clinical effect of Yiqi Qiangxin Decoction on patients with chronic heart failure

Evaluation of clinical effect of Yiqi Qiangxin Decoction on patients with chronic heart failure

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084461
Enrollment
Unknown
Registered
2024-05-16
Start date
2024-05-16
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Yiqi Qiangxin Tang:The treatment group was given Yiqi Qiangxin Tang (a traditional Chinese medicine granule, one dose per day, twice a day, provided by the Traditional Chinese Medicine Granule Pharmac
duizhaozu:Western medicine therapy

Sponsors

Dongzhimen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the above diagnostic criteria for Western Medicine HFmrEF (NYHA Grade II-III) and TCM Qi-deficiency and blood-stasis syndrome; (2) Age 18-75 years old, male or female; (3) Able to communicate orally and in writing; (4) Those who voluntarily participate in the study, can obey the treatment plan, and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of acute heart failure within the last 30 days; (2) The main right heart dysfunction; (3) Those who are unable to complete the relevant examination of this study due to activities inconvenience or other reasons; (4) Patients with a history of malignant tumor requiring regular radiotherapy and chemotherapy; (5) Patients with rheumatoid arthritis, lupus erythematosus and other diseases, who need to take immunosuppressants regularly; (6) Patients with abnormal liver function (ALT, AST or ALP=3× upper limit of normal); (7) Patients with severe renal insufficiency (estimated glomerular filtration rate eGFR < 30 ml/(min·1.73m2); (8) Obvious hemodynamic changes caused by left ventricular outflow tract obstruction, aortic aneurysm, aortic dissection or unrepaired valve; (9) Patients who are known to be allergic to the drugs or drug ingredients used in this study; (10) Women who are pregnant or planning to become pregnant and breastfeeding.

Design outcomes

Primary

MeasureTime frame
nt-probnp;

Secondary

MeasureTime frame
echocardiography;The six-minute walk test;NYHA cardiac function classification;ECG;

Countries

China

Contacts

Public ContactChangPeiFen

none

13661022016@163.com+86 136 6102 2016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026